Analysts at Kotak Neo suggest that recent market corrections have brought valuations to 16 times projected FY28 earnings, potentially creating long-term opportunities. While volatility continues and foreign institutional investors remain cautious, stabilizing macro factors like the Indian rupee and lower US bond yields could offer support. However, investors are advised to navigate sectoral risks carefully, particularly in the auto and healthcare segments.
Indian equity markets have experienced a correction recently, with the broader market retreating 10% to 15% from its previous highs. According to the equity research team at Kotak Neo, these price levels are becoming increasingly attractive for long-term investors, with valuations now trading at approximately 16 times earnings estimates for the 2028 financial year.
While mid-cap and small-cap stocks continue to face sharp volatility, the Nifty index is finding potential support in the 21,750 to 21,800 range. Analysts view these fluctuations as part of a typical market correction rather than a sign of a structural breakdown in the economy.
Macroeconomic Influences
The stabilization of the Indian rupee remains a crucial factor for market confidence. Proactive management by the Reserve Bank of India, combined with capital inflows from recent public share offerings, has helped anchor the currency after it faced downward pressure. Additionally, US bond yields have eased to 4.95%, dropping from earlier highs of 5.30%. This reduction in global yields is generally considered a positive factor for emerging market assets. Although foreign institutional investors have been consistent sellers, the intensity of these outflows has noticeably slowed over the last two weeks.
Sectoral Divergence and Risks
Strategic positioning currently favors specific areas over others. Research notes suggest long-term potential in mid-sized information technology firms, private sector banks, and the hospitality and tourism sectors. Conversely, the outlook for automobile stocks remains cautious, weighed down by higher crude oil prices and tepid earnings growth.
Investors are also cautioned against blindly increasing exposure to the pharmaceutical sector. These stocks have witnessed an aggressive rally over the last six months, leaving their current valuations looking stretched. Furthermore, hospital chains are contending with heightened regulatory scrutiny, a factor that could impact future operational flexibility. This mix of opportunity and risk highlights the importance of selective investing rather than broad-market allocation.
Moving forward, the primary factors for investors to track include the pace of foreign capital flows, fluctuations in global crude oil prices, and the quality of upcoming quarterly corporate results. These elements will determine whether the current valuation levels are sustained or if further volatility lies ahead.